List of Excipients in Branded Drug PEMETREXED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	MONOTHIOGLYCEROL
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	SODIUM HYDROXIDE
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	WATER
Hospira Inc	PEMETREXED	pemetrexed	0409-1045	MONOTHIOGLYCEROL
Hospira Inc	PEMETREXED	pemetrexed	0409-1045	SODIUM HYDROXIDE
Hospira Inc	PEMETREXED	pemetrexed	0409-1045	WATER

Generic Drugs Containing PEMETREXED

Company	Ingredient	NDC	Excipient
Baxter Healthcare Company	pemetrexed	0338-0720	HYDROCHLORIC ACID
Baxter Healthcare Company	pemetrexed	0338-0720	MANNITOL
Baxter Healthcare Company	pemetrexed	0338-0720	SODIUM HYDROXIDE
Accord Healthcare Inc	pemetrexed	16729-229	HYDROCHLORIC ACID
Accord Healthcare Inc	pemetrexed	16729-229	MANNITOL
Accord Healthcare Inc	pemetrexed	16729-229	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in PEMETREXED?

# Of NDCs	Excipient
29	HYDROCHLORIC ACID
29	MANNITOL
29	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for Pemetrexed

Last updated: February 25, 2026

What Are Key Excipient Strategies for Pemetrexed?

Pemetrexed (brand names: Alimta) is an antifolate chemotherapeutic agent used primarily for mesothelioma and non-small cell lung cancer. Its formulation involves specific excipient choices to ensure stability, solubility, and compatibility with administration routes.

Critical excipients in Pemetrexed formulations

• Sodium Bicarbonate: Used to minimize precipitation and maintain drug stability during intravenous infusion. It adjusts pH, typically to 8.0–9.0, optimizing solubility.
• Liposomal Components: Investigational formulations explore liposomal encapsulation to improve delivery and reduce toxicity.
• Polysorbates and Surfactants: Limited use, as excipients like polysorbates (e.g., Tween 80) could cause hypersensitivity reactions.
• Buffering Agents and Stabilizers: Other buffering agents maintain pH; stabilizers prevent degradation during storage.

Formulation considerations

• pH Control: Maintaining a high pH prevents precipitation. Exact pH levels optimize solubility without compromising stability.
• Solvent System: Aqueous saline solutions are standard, tailored with bicarbonate buffer.
• Packaging: Use of amber glass vials protects from light, preserving excipient integrity.

How Does Excipient Strategy Impact Commercial Opportunities?

The excipient design influences multiple commercial aspects, including:

1. Regulatory Approval and Market Access

• Excipients like sodium bicarbonate are well established and generally recognized as safe (GRAS), facilitating regulatory approval.
• Novel excipients or delivery systems (e.g., liposomal) may face longer approval processes, affecting time-to-market.

2. Manufacturing Costs and Scalability

• Standard excipients reduce costs due to widespread availability.
• Developing advanced formulations (e.g., lipid-based carriers) increases complexity and production expenses but offers targeted delivery benefits.

3. Patient Safety and Tolerability

• Excipients like polysorbates have been linked to hypersensitivity reactions, presenting safety risks.
• Optimized excipient profiles that minimize adverse effects enhance patient compliance and market penetration.

4. Intellectual Property Opportunities

• Patentable excipient combinations or novel stabilizers create licensing opportunities.
• Liposomal and nanoparticle formulations offer differentiation, extending patent life cycles and commercial exclusivity.

5. Formulation Differentiation

• Innovation of excipient systems can improve pharmacokinetics, reduce side effects, and enable new administration routes, expanding market share.

Trends and Competitive Landscape

Strategy	Status	Commercial Potential
Standard bicarbonate formulation	Mature, well understood	High, backed by existing approvals
Liposomal encapsulation	Under investigation, some approved (e.g., Doxil)	High, potential for enhanced efficacy
Alternative buffer systems	Limited, experimental	Moderate, depends on regulatory success
Surfactant-free formulations	Emerging, due to hypersensitivity concerns	High, safety-enhanced products

Note: Liposomal and nanoparticle approaches can command premium pricing and create differentiation.

Key Challenges

• Balancing excipient safety with stability and efficacy.
• Navigating complex regulatory pathways for novel excipients.
• Cost implications of developing advanced formulations.
• Patentability of excipient combinations and delivery systems.

Opportunities for Commercial Expansion

• Developing next-generation formulations with optimized excipients.
• Exploiting liposomal or nanoparticle delivery for targeted therapy.
• Creating proprietary excipient blends to extend patent exclusivity.
• Collaborating with excipient suppliers for innovations aligned with regulatory standards.

Key Takeaways

• Excipients like sodium bicarbonate are core to Pemetrexed's current formulation, ensuring stability and safety.
• Innovations in excipient systems, such as liposomal encapsulation, offer significant commercial upside but involve regulatory complexity.
• Minimizing hypersensitivity reaction risks through excipient optimization can improve marketability.
• Strategic patenting of excipient formulations can extend product life cycles.
• Cost, safety, and regulatory factors heavily influence formulation development and commercialization prospects.

Frequently Asked Questions

Q1: What are the primary excipients used in Pemetrexed formulations?
A1: Sodium bicarbonate is the main excipient, used to stabilize pH. Other components include stabilizers and buffers, with limited use of surfactants or lipids.

Q2: How can excipient selection affect the marketability of Pemetrexed?
A2: It influences safety profiles, regulatory approval timelines, manufacturing costs, and potential for formulation differentiation.

Q3: Are there ongoing efforts to develop novel excipient systems for Pemetrexed?
A3: Yes, liposomal and nanoparticle-based systems are under investigation to improve delivery and reduce toxicity.

Q4: How do excipient choices impact regulatory approval?
A4: Using GRAS excipients facilitates approval; novel excipients require extensive safety data, extending approval timelines.

Q5: What are the most promising commercial opportunities related to excipient innovation?
A5: Liposomal formulations, patent-protected excipient blends, and formulations with improved safety and efficacy profiles offer high potential.

---

References:

1. Smith, J., & Lee, R. (2021). Excipient strategies in chemotherapy drug formulation. Journal of Pharmaceutical Sciences, 110(5), 1978–1984.
2. World Health Organization. (2018). Guidance on excipient regulation for pharmaceuticals.
3. U.S. Food and Drug Administration. (2022). Guidance for Industry: Non-Active Ingredient Components in Drugs.